Media Articles Related to Ganirelix
A single mutation in the beta-catenin gene can lead to infertility
Source: Fertility News From Medical News Today [2014.11.10]
Scientists from the RIKEN BioResource Center in Tsukuba, Japan, have discovered that a single mutation in the beta-catenin gene, which codes a protein known to be deeply involved in a number of...
Ovarian tissue and egg freezing should be made widely available to prevent age-related infertility, say leading fertility experts
Source: Fertility News From Medical News Today [2014.10.03]
Ovarian tissue and egg freezing to preserve fertility should no longer be reserved for cancer patients, and healthy women should also be offered these options to safeguard their future chances of...
Infertility: Ten Questions to Ask Your Doctor About Infertility
Source: MedicineNet Endometriosis Specialty [2014.09.12]
Title: Infertility: Ten Questions to Ask Your Doctor About Infertility
Category: Doctor's & Expert's views on Symptoms
Created: 6/21/2005 12:00:00 AM
Last Editorial Review: 9/12/2014 12:00:00 AM
Breast Cancer Drug May Help Women Fight a Leading Cause of Infertility: Study
Source: MedicineNet letrozole Specialty [2014.07.10]
Title: Breast Cancer Drug May Help Women Fight a Leading Cause of Infertility: Study
Category: Health News
Created: 7/9/2014 5:36:00 PM
Last Editorial Review: 7/10/2014 12:00:00 AM
Cycling and risk for erectile dysfunction, infertility, prostate cancer
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2014.07.08]
Cycling is a popular activity that offers clear health benefits, but there is an ongoing controversy about whether men who ride have a higher risk of urogenital disorders such as erectile...
Published Studies Related to Ganirelix
A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011.06.30]
We performed a randomized trial to compare IVF outcomes in 54 poor responder patients undergoing a microdose leuprolide acetate (LA) protocol or a GnRH antagonist protocol incorporating a luteal phase E(2) patch and GnRH antagonist in the preceding menstrual cycle.
The effect of cetrorelix vs. ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels. 
CONCLUSIONS: The trend for lower pregnancy rates with ganirelix vs. cetrorelix seen in women with diminished egg reserve is consistent with the findings of a study performed in women with normal egg reserve using a normal gonadotropin stimulation regimen. It is not clear if the adverse effect is on the endometrium or the embryo.
Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. [2006.03]
BACKGROUND: This study was designed to assess whether the use of ganirelix in women undergoing stimulated IUI could prevent the occurrence of premature LH rises and luteinization (LH+progesterone rises)... CONCLUSIONS: Treatment with ganirelix effectively prevents premature LH rises, luteinization in subjects undergoing stimulated IUI. Low-dose rFSH regimen combined with a GnRH antagonist may be an alternative treatment option for subjects with previous proven luteinization or in subjects who would otherwise require insemination when staff are not working.
LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome. [2005.12]
Elevated LH concentration is a common feature in polycystic ovary syndrome (PCOS). This study was designed to establish whether elevated LH levels in PCOS might be suppressed to normal range values by the administration of different low doses of GnRH antagonist, which subsequently might reverse the anovulatory status of these patients...
Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. [2005.07]
OBJECTIVE: To compare the safety and efficacy of single-dose cetrorelix acetate (3 mg) and daily ganirelix acetate (0.25 mg) in the inhibition of premature LH surge in women undergoing cycle-programmed ovarian stimulation before Assisted Reproductive Technology (ART).CONCLUSION(S): Cetrorelix and ganirelix effectively prevented LH surges in oral contraceptive (OC) pill-programmed, flexible protocols, with similar safety profiles and PRs; however, cetrorelix required significantly fewer injections, increasing patient convenience.
Clinical Trials Related to Ganirelix
Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles [Recruiting]
Ovulation induction (OI) using gonadotropins is one of the most widely prescribed treatments
of infertility. One common problem encountered while attempting OI using gonadotropins is
premature ovulation. The purpose of this study is to examine the effect of a single
injection of a medication, called ganirelix, to prevent premature ovulation. Patients will
be divided into two groups. In the first group, gonadotropins will be used to stimulate the
ovaries. In the second group gonadotropins will be used in addition to a single injection
of ganirelix, a gonadotropin releasing hormone (GnRH) antagonist. Pregnancy rates will be
compared between groups.
Sex Hormones and Orthostatic Tolerance [Recruiting]
This study is designed to determine the causes of "orthostatic intolerance" which occurs
more commonly in women than in men. Orthostatic tolerance is the ability to remain standing
up right for long periods of time, or to avoid dizziness when moving to standing from a
seated or lying position.
Delayed Start to Ovarian Stimulation [Recruiting]
In couples with infertility secondary to Diminished Ovarian Reserve, the investigators
hypothesize that a delayed start (7 day) to ovarian stimulation with an GnRH antagonist
(Ganirelix) will improve oocyte maturation and quality, and improve pregnancy outcomes.
An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029) [Not yet recruiting]
This study, conducted in India, will be recruiting women participants who are between the
ages of 18 and 42, and who have an indication for controlled ovarian stimulation (COS), but
have not yet undergone in-vitro fertilization and/or intracytoplasmic sperm injection
(IVF/ICSI). The study is designed to compare the difference in oocyte (immature egg cell)
production after administration of the investigative drug, MK-8962 (corifollitropin alfa) +
recombinant follicle stimulating hormone (recFSH), in contrast to use of only the reference
Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation [Recruiting]
The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in
oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes
donors . This study will be performed in egg recipients and donors but this type of
treatment is meant to be implemented in fertility preservation patients